Noventra Pharma | Tirreta Hybrid 60mg | Multi-Dose Compound Peptide Pen
High-Strength Hybrid Multi-Peptide Research Compound
Tirreta is a hybrid investigational peptide formulation designed for scientific research into multi-compound peptide systems and complex biological interaction pathways.
It is referenced in laboratory research exploring peptide synergy, receptor interaction dynamics, and multi-pathway signalling models within controlled experimental environments.
Developed as a 60mg multi-dose research compound, this formulation is designed for advanced laboratory investigation where combined peptide behaviour profiling and extended activity analysis are of interest.
Key Benefits – Noventra Pharma Tirreta Hybrid Compound Peptide Pen 60mg (Multi-Dose)
• Hybrid multi-peptide research formulation for laboratory investigation
• Investigated in multi-pathway peptide interaction and synergy research models
• Of interest in experimental peptide combination studies
• 60mg multi-dose research formulation for controlled laboratory use
• Studied in advanced peptide behaviour and signalling research contexts
• Pre-filled multi-dose pen format designed for consistent handling
• High-purity compounded formulation from Noventra Pharma
• Manufactured for stability, consistency, and research reliability
⚖️ DISCLAIMER
This product is intended strictly for laboratory research purposes only. It is not a medicine and has not been evaluated or approved by the South African Health Products Regulatory Authority (SAHPRA) for human or animal use.
This product is supplied strictly for laboratory research purposes only and is not intended for human consumption.
Products sold on this website are not intended to diagnose, treat, cure, or prevent any disease.
By purchasing, the customer confirms they are qualified to handle and use this product in accordance with applicable laws and regulations.
